Business Context and Reporting Period
This Form 8-K was filed by ReWalk Robotics Ltd. (noted as Lifeward Ltd. in metadata) on March 23, 2018. The report discloses events occurring on March 6, 2018, regarding a strategic investment and a potential joint venture in China.
Key Financial Metrics
The filing details a capital raise transaction but does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels for the reporting period.
- Investment Proceeds: $20 million (aggregate gross proceeds).
- Equity Issuance: 16,000,000 ordinary shares issued to the investor.
- Share Par Value: NIS 0.01 per share.
Material Changes
The primary material change is the execution of two agreements on March 6, 2018:
- Investment Agreement: Entered into with Timwell Corporation Limited (Hong Kong) for the issuance of shares in exchange for $20 million.
- Joint Venture Framework: Entered into with RealCan Ambrum Healthcare Industry Investment (Shenzhen) Partnership Enterprise, an affiliate of the investor, to form a joint venture company in China.
Guidance, Outlook, and Risks
Management Commentary and Process: The company states that a definitive proxy statement will be filed to seek shareholder approval for the transaction. Investors are urged to read this future document for important details.
Risks and Contingencies:
- Registration Status: The shares issued to the investor are not registered under the Securities Act of 1933 and cannot be offered or sold in the United States without registration or an exemption.
- Representations and Warranties: The agreements contain customary representations and warranties subject to exceptions and limitations; third parties should not rely on these for factual characterizations.
- Confidentiality: Portions of the Investment Agreement and JV Framework Agreement have been redacted for confidential treatment.
Investor Verification Checklist
- Verify the final terms of the transaction in the upcoming definitive proxy statement.
- Confirm the dilution impact of the 16,000,000 new shares on existing shareholders.
- Review the specific terms of the China joint venture once the framework is finalized.
- Monitor the status of the $20 million capital infusion and its intended use.